Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

New Mechanism of DME Treatment Highlights Clinical Trial Updates

12 October 2026 · By · Wire by Fusion42

Published

12 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at ajmc.com →

◆ Verified

Fusion42 · 12 October 2026 · Fusion42 review

The BRUNELLO trial presented results showing remigromig, a novel biologic activating the Wnt pathway, achieved noninferior visual outcomes compared to anti-VEGF ranibizumab for diabetic macular edema (DME). Separate trials MEERKAT and SANDCAT explore vamikibart, an anti-IL-6 antibody, as a new treatment for uveitic macular edema (UME).

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can reframe diabetic eye disease treatments beyond anti-VEGF by focusing on remigromig’s Wnt pathway method, opening differentiation in a crowded space. Vamikibart’s anti-IL-6 for uveitic macular edema signals fresh opportunity in tough-to-treat retinal conditions.

◆ Coverage

1 source · 12 Oct 2026

◆ Related on Wire

◆ Topics

Medtechdmeclinical-trialophthalmologynovel-therapyuveitic-macular-edema